David Guay
Vice President, Innovation & Technology Feldan Therapeutics
David Guay is the Research Director at Feldan Therapeutics since 2009. Dr. Guay received his PhD in molecular and cell biology from Laval University for its research on the implication of a transcription factor in DNA repair and chemotherapy resistance mechanisms. He holds a postdoctoral fellowship in chemical engineering from McGill University where he developed a DNA delivery technique based on a non-thermal plasma technology. His research at Feldan Therapeutics focuses on the “Feldan Shuttle”, a peptide-based technology designed to deliver native proteins, namely transcription factors, antibodies and CRISPR nucleases, in therapeutic cells.
Seminars
Wednesday 10th December 2025
Panel Discussion: Turning Setbacks into Strategy, what Clinical Trial Failures Teach us About Building Better Oligonucleotide Therapies
9:00 am
- Unpack the reasons behind trial discontinuations: Was it the oligo, delivery system, or something else?
- Discuss how teams rebounded, what pivots, partnerships, or reformulations turned failure into future success
Thursday 11th December 2025
Maximizing Therapeutic Succes: Choosing the Right Oligonucleotide, Delivery Vehicle & Administration Route
12:00 pm
- Shuttle peptide platform: Efficient endosomal escape driving the development of PMO-based therapeutics
- Development of a non-surgical therapeutic for basal cell carcinoma administered by intralesional injection
- Efficient delivery to airway epithelial cells, advancing inhaled PMO therapies for muco-obstructive lung diseases
